Obesity therapeutics to 2019 At Researchmoz

219 views

Published on

Research, the leading business intelligence provider, has released its latest research: Obesity Therapeutics to 2019 – Safety Concerns Hinder Drug Performance Despite Large Market Opportunity”. Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs.

Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical’s Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use. As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a major barrier to the growth of the anti-obesity therapeutics market. Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and GBI Research believes that only one, Vivus’ Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies.

View Detail Report With TOC At : http://www.researchmoz.us/obesity-therapeutics-to-2019-safety-concerns-hinder-drug-performance-despite-large-market-opportunity-report.html

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
219
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Obesity therapeutics to 2019 At Researchmoz

  1. 1. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity GBI Research, the leading business intelligence provider, has released its latest research: Obesity Therapeutics to 2019 – Safety Concerns Hinder Drug Performance Despite Large Market Opportunity”. Obesity is often described as a global endemic, with incidence dramatically increasing over the past decades, particularly in developed countries. Being overweight or obese is a major risk factor in the development of many chronic diseases, including cardiovascular diseases, cancer, and diabetes, of which treatment incurs extensive economic and healthcare costs. Numerous anti-obesity drugs have been approved in the past decade, including Knoll Pharmaceutical’s Meridia (sibutramine) and Acomplia (rimonabant), only for them to be removed from the market due to evidence of suicidal thoughts, depression and cardiovascular problems with their long-term use. As such, healthcare professionals have a negative perception of such drugs and do not widely prescribe them, a major barrier to the growth of the anti-obesity therapeutics market. Only orlistat is currently deemed safe for the long-term treatment of obesity; being proven to produce a placebo-adjusted weight-loss average of a limited 3kg. Two anti-obesity drugs were approved in June and July 2012, and GBI Research believes that only one, Vivus’ Qsymia, has a strong enough safety and efficacy (average placebo-adjusted weight loss of 5kg at the medium dose) profile to make a significant impact on the market, providing it is proven safe in long-term-use studies. If proven safe, GBI Research expects the sales of Qsymia and other drugs expected to be approved over the forecast period to increase the market size to $2.7 billion. Although moderate, this is significantly below the market potential given the size of the prevalence population. Optimally safe and effective anti-obesity drugs which overcome healthcare professionals’ negative opinions will have to be developed if the size of the market is ever to reflect the prevalence of obesity. Scope The report analyzes the incidence of obesity, current treatment options, pipeline and market forecasts, and deals surrounding anti-obesity drugs. The report includes: A brief introduction to obesity; detailed analysis of recent, current and projected incidence trends; co-morbidities; economic implications of their treatment; and the current treatment options Analysis of the currently marketed anti-obesity drugs, including recent sales figures, safety and efficacy data, and a discussion of each drug’s expected performance within the forecast period Comprehensive reviews of the pipeline for anti-obesity drugs, including analysis by molecule type and mechanism of action Statistical analysis of clinical trial duration, size, and failure rate by Phase and molecule type An in-depth forecast model for the anti-obesity drugs market in the US, UK, France, Germany, Italy, Spain and Japan. Each model is based on the anticipated market performance of marketed drugs and those expected to be approved within the forecast period, and takes into account drug cost, efficacy, safety, and likely prescription volumes. A detailed discussion of the drivers and barriers for this immature market Reasons to Buy The report will enhance your decision-making capability by allowing you to: Understand the large number of potential molecular targets for the development of an anti-obesity drug, as Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
  2. 2. well as the strengths, weaknesses, and risks of each drug type Gain an in-depth view of the current status of the anti-obesity drug pipeline, including the most common molecular targets and molecule types in development Observe the trends in clinical trial duration and size by Phase, molecule type and mechanism of action, and use the clinical trial failure rate analysis to assess the risk profiles of current and future developmental programs Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the anti-obesity drugs market Analyze current and past deals surrounding anti-obesity drugs, including their value, year of deal and in depth details of the highest value deals table Of Contents 1 Table Of Contents 1.1 List Of Tables 1.2 List Of Figures 2 Introduction 2.1 Etiology And Pathophysiology 2.2 Classification 2.3 Epidemiology 2.3.1 The Us 2.3.2 Obesity In The Top Five European Markets 2.3.3 Japan 2.4 Comorbidities 2.4.1 Type 2 Diabetes 2.4.2 Hypertension 2.4.3 Dyslipidemia 2.4.4 Respiratory Problems 2.4.5 Osteoarthritis 2.4.6 Cancer Risk 2.5 Economic Burden 2.6 Current Therapy Options 2.6.1 Lifestyle And Behavioral Modifications 2.6.2 Bariatric Surgery 2.6.3 Pharmacotherapy 2.6.4 Treatment Algorithms And Prescription Habits 2.6.5 Method Of Determining Treatment Effectiveness 2.7 Why Develop Therapeutic Anti-obesity Drugs? 2.8 Gbi Research Report Guidance 3 Marketed Products 3.1 Amphetamine-like Drugs Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
  3. 3. 3.1.1 Overview 3.1.2 Efficacy Profile 3.1.3 Safety Profile 3.2 Qsymia, Vivus, Inc. 3.2.1 Overview 3.2.2 Efficacy Profile 3.2.3 Safety Profile 3.2.4 Discussion 3.3 Orlistat 3.3.1 Overview 3.3.2 Efficacy Profile 3.3.3 Safety Profile 3.3.4 Discussion 3.4 Belviq, Arena Pharmaceuticals 3.4.1 Introduction 3.4.2 Efficacy Profile 3.4.3 Safety Profile 3.4.4 Discussion 3.5 Low Long-term Success Rate Of Marketed Anti-obesity Drugs 3.6 Discussion 4 Pipeline 4.1 Overview Of Pipeline By Phase, Molecule Type And Molecular Target 4.2 Clinical Trial Duration And Size 4.2.1 Clinical Trial Duration 4.2.2 Clinical Trial Size 4.3 Clinical Trial Failure, Attrition Rate And Reasons For Clinical Trial Failure 4.4 Primary And Secondary Endpoints 4.5 Late-stage Drugs Of The Developmental Pipeline 4.5.1 Contrave, Orexigen Therapeutics 4.5.2 Cametor, Norgine Bv 4.5.3 Victoza, Novo Nordisk 4.5.4 Tesofensine (neurosearch) 4.6 Discussion 5 Market Forecasts 5.1 Global Market 5.2 The Us 5.2.1 Epidemiology And Treatment Usage Patterns 5.2.2 Annual Cost Of Therapy 5.2.3 Market Size Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
  4. 4. 5.3 Europe 5.3.1 Treatment Usage Patterns 5.3.2 Annual Cost Of Therapy 5.3.3 Market Size 5.4 Japan 5.4.1 Treatment Usage Patterns 5.4.2 Annual Cost Of Therapy 5.4.3 Market Forecast 5.5 Discussion 5.6 Drivers And Barriers Of The Anti-obesity Market 5.7 Obesity Market Drivers 5.7.1 Obesity Is A Very Prevalent Disease With Large Potential Target Populations Globally 5.7.2 Recent Approval Of Qsymia To Drive Market Growth Providing Its Long-term Safety Is Proved 5.7.3 Diversification Of Molecular Targets 5.8 Obesity Market Barriers 5.8.1 Low Treatment Rate 5.8.2 Reimbursement Issues 6 Licensing And Co-development Deals 6.1 Licensing Deals 6.1.1 Emd Serono Enters Into Collaboration And Licensing Agreement With Theratechnologies 6.1.2 Amylin Pharma Enters Into Licensing Agreement With Takeda Pharma 6.1.3 Palatin Technologies Extends License Agreement With Astrazeneca 6.1.4 Zealand Pharma Enters Into Licensing And Collaboration Agreement With Boehringer ingelheim 6.2 Co-development Deals 6.2.1 Isis Enters Into Collaboration Agreement With Ortho-mcneil 6.2.2 Orexigen Therapeutics Enters Into Co-development Agreement With Takeda Pharma For contrave 7 Appendix 7.1 References 7.2 Abbreviations 7.3 All Pipeline Drugs By Phase 7.3.1 Discovery 7.3.2 Preclinical 7.3.3 Phase I 7.3.4 Phase Ii 7.3.5 Phase Iii 7.3.6 Pre-registration 7.4 Market Forecasts To 2019 Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
  5. 5. 7.4.1 Global 7.4.2 The Us 7.4.3 Uk 7.4.4 France 7.4.5 Germany 7.4.6 Italy 7.4.7 Spain 7.4.8 Japan 7.5 Methodology 7.6 Secondary Research 7.7 Therapeutic Landscape 7.8 Epidemiology-based Forecasting 7.9 Market Size By Geography 7.10 Pipeline Analysis 7.11 Contact Us 7.12 Disclaimer ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

×